Work

Precision treatment for human epidermal growth factor receptor 2-amplified advanced rectal cancer: A case report

Year: 2025

Type: article

Abstract: BACKGROUND: Although targeted therapy provides survival benefits for patients with metastatic colorectal cancer, some patients develop resistance to these treatments. Human epidermal growth factor receptor 2 (HER2) is overexpressed in a subset of patients with colorectal cancer and has been established as a therapeutic target. CASE SUMMARY: This case report describes a Chinese patient with HER2-amplified advanced rectal cancer who showed no response to chemotherapy and targeted therapies against epidermal growth factor receptor and vascular endothelial growth factor but achieved a remarkable response following treatment with immune checkpoint inhibitors (ICIs) in combination with pyrotinib. The combination of oxaliplatin and ICIs with pyrotinib demonstrates synergistic effects after late-stage disease progression. CONCLUSION: ICIs and pyrotinib may be effective in treating HER2-amplified advanced rectal cancer. Chemotherapy following disease progression could enhance efficacy synergistically.

Source: World Journal of Gastrointestinal Oncology

DOI: 10.4251/wjgo.v17.i4.102690

Authors: Xia Xiao, Qing-Wen Wang, Zheng-Yang Zhou, Lei-Sheng Wang, Pei Huang

Institutions: Jiangnan University, Wuxi No.2 People's Hospital

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

Funder: Merck KGaA